1. Home
  2. RARE vs BKU Comparison

RARE vs BKU Comparison

Compare RARE & BKU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RARE
  • BKU
  • Stock Information
  • Founded
  • RARE 2010
  • BKU 2009
  • Country
  • RARE United States
  • BKU United States
  • Employees
  • RARE N/A
  • BKU N/A
  • Industry
  • RARE Biotechnology: Pharmaceutical Preparations
  • BKU Savings Institutions
  • Sector
  • RARE Health Care
  • BKU Finance
  • Exchange
  • RARE Nasdaq
  • BKU Nasdaq
  • Market Cap
  • RARE 3.2B
  • BKU 2.8B
  • IPO Year
  • RARE 2014
  • BKU 2011
  • Fundamental
  • Price
  • RARE $33.00
  • BKU $40.68
  • Analyst Decision
  • RARE Strong Buy
  • BKU Hold
  • Analyst Count
  • RARE 15
  • BKU 12
  • Target Price
  • RARE $87.00
  • BKU $41.67
  • AVG Volume (30 Days)
  • RARE 1.4M
  • BKU 1.1M
  • Earning Date
  • RARE 11-04-2025
  • BKU 10-22-2025
  • Dividend Yield
  • RARE N/A
  • BKU 3.06%
  • EPS Growth
  • RARE N/A
  • BKU 44.85
  • EPS
  • RARE N/A
  • BKU 3.54
  • Revenue
  • RARE $630,598,000.00
  • BKU $1,016,093,000.00
  • Revenue This Year
  • RARE $19.65
  • BKU $14.68
  • Revenue Next Year
  • RARE $23.65
  • BKU $5.82
  • P/E Ratio
  • RARE N/A
  • BKU $11.44
  • Revenue Growth
  • RARE 20.63
  • BKU 10.45
  • 52 Week Low
  • RARE $25.81
  • BKU $28.21
  • 52 Week High
  • RARE $53.04
  • BKU $44.45
  • Technical
  • Relative Strength Index (RSI)
  • RARE 52.70
  • BKU 60.45
  • Support Level
  • RARE $29.36
  • BKU $39.51
  • Resistance Level
  • RARE $35.95
  • BKU $40.80
  • Average True Range (ATR)
  • RARE 1.60
  • BKU 1.16
  • MACD
  • RARE -0.36
  • BKU 0.16
  • Stochastic Oscillator
  • RARE 60.79
  • BKU 84.43

About RARE Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

About BKU BankUnited Inc.

BankUnited Inc is a bank holding company with one wholly owned subsidiary, BankUnited. The bank provides a full range of banking services through banking centers located throughout Florida, as well as New York City. The company is a commercially focused regional bank focusing on small and middle-market businesses, but also provides certain commercial lending and deposit products on a national platform. The Bank offers a comprehensive suite of commercial lending and deposit products through an Atlanta office focused on the Southeast region, certain commercial lending and deposit products through national platforms and certain consumer deposit products through an online channel.

Share on Social Networks: